Astaxanthin plus berberine: a nutraceutical strategy for replicating the benefits of a metformin/fibrate regimen in metabolic syndrome

James J DiNicolantonio, Mark McCarty, James O'Keefe

BERBERINE IS A NUTRACEUTICAL ACTIVATOR OF AMP-ACTIVATED KINASE

The phytochemical berberine, a constituent of certain herbs used in traditional Chinese medicine, has long been in use in China as a well-documented therapy for type 2 diabetes. Mechanistic studies demonstrate that, like metformin, it activates AMP-activated kinase (AMPK); this is thought to be the chief basis of its utility in diabetes. The typical therapeutic regimen is 500 mg/2 or three times per day, or 850 mg two times per day. The most common side effect is constipation, which tends to remit during continuing treatment. Unlike metformin, however, berberine upregulates the hepatic expression of LDL receptors, through a mechanism that is complementary to that of statins or red yeast rice (RYR); whereas statins increase transcription of the gene coding for LDL receptors, berberine increases the half-life of LDL receptor mRNA. Hence, the combination of berberine plus RYR—a natural low-potency source of monacolin K (lovastatin) and other monacolins that has moderate hypcholesterolaemic activity in a standardised dose that is well tolerated in most patients who don’t tolerate pharmaceutical statins—has been recommended as a nutraceutical alternative to pharmaceutical drugs in the management of hypercholesterolaemia.

THE CAROTENOID ASTAXANTHIN CAN ACT AS A PPAR\(\alpha\) AGONIST

The natural carotenoid astaxanthin is extraordinarily effective—more so than tocopherols—for conferring radical-scavenging antioxidant protection to biological membranes. It may be particularly beneficial for blunting the feedforward loop whereby mitochondria subjected to oxidative stress—as during ischaemia-reperfusion injury—become greater sources of oxidants owing to damage to their respiratory chains. However, in both clinical and rodent studies, oral astaxanthin has ameliorated the dyslipidaemia and hepatic steatosis associated with metabolic syndrome, suggesting that it has an additional target of action. Indeed, there is recent evidence that, in concentrations that can be achieved through oral administration at practical doses, astaxanthin can act as a PPAR\(\alpha\) agonist. In other words, astaxanthin has the potential to replicate the activity of PPAR\(\alpha\) agonist drugs, such as the fibrates, which are known to decrease risk for cardiovascular events in patients with metabolic syndrome. In a recent placebo-controlled trial enrolling patients with type 2 diabetes, astaxanthin (8 mg daily for 8 weeks) achieved significant reductions in serum triglycerides (156–128 mg/dL), serum fructosamine (7.4–5.8 \(\mu\)mol/L) and systolic blood pressure (143–132 mm Hg), while significantly elevating adiponectin (36–47 \(\mu\)g/mL); these parameters all worsened non-significantly in the placebo group.

AMPK AND PPAR\(\alpha\) AGONISTS REINFORCE EACH OTHER’S UTILITY IN METABOLIC SYNDROME

The combination of metformin and fenofibrate has been studied in patients with type 2 diabetes and metabolic syndrome, and has been found more effective for improving lipid profiles and aiding glycaemic control than either agent alone. This likely reflects the fact that AMPK and PPAR\(\alpha\) interact in mutually complementary ways to promote efficient mitochondrial oxidation of fatty acids, thereby lessening hepatic triglyceride synthesis and decreasing the exposure of tissues to ectopic fat.

The transcription factor PPAR\(\alpha\), after forming a heterodimer with the retinoid
X receptor, stimulates the transcription of genes which promote mitochondrial oxidation of fatty acids and ketogenesis, including carnitine palmitoyl transferases (CPT) 1a and 2, acyl-coenzyme A oxidase and uncoupling protein 2. The favourable impact of PPARα agonists on human HDL levels reflects the induction of apolipoproteins A-I and A-II—an effect not observed in rodents. X6 X7 PPARα also stimulates hepatic production of fibroblast growth factor 21 (FGF21), a 'pro-longevity' hormone which acts on adipocytes to boost their production of adiponectin; the latter, in turn, acts on hepatocytes and other tissues to stimulate AMPK activity. X8–X10

Although there is no evidence that AMPK directly phosphorylates PPARα to influence its transcriptional activity, AMPK acts to increase both the expression and activity of PPARγ coactivator-1a (PGC-1a), which serves as a coactivator for PPARα as well as for several other transcription factors that promote mitochondrial biogenesis. X39–X43 Also, in some cellular contexts, AMPK boosts the expression of PPARα, likely by promoting nuclear translocation of transcription factor EB, a master regulator of autophagy and lysosomal activity; this effect might also be partially attributable to enhanced PGC-1α activity, as PPARα acts to drive transcription of its own gene. X44–X49 Importantly, AMPK complements PPARα impact on mitochondrial fatty acid oxidation by lowering cytoplasmic levels of malonyl-coenzymeA, an allosteric inhibitor of CPT-1a; it does so by conferring inhibitory phosphorylation on acetyl-coenzymeA carboxylase, and activating phosphorylation on malonyl-coenzymeA decarboxylase, X50 X51 and AMPK decreases hepatic triglyceride synthesis both by directing free fatty acids towards mitochondrial oxidation, as well as by suppressing the activity of rate-limiting enzyme for triglyceride synthesis, glycerol-3-phosphate acyltransferase. X52 Concurrently, AMPK inhibits hepatic gluconeogenesis, an effect in large part responsible for the favourable impact of AMPK agonists on glycaemic control in diabetics; a rate-limiting enzyme for gluconeogenesis, fructose-1,6-bisphosphatase, has recently been identified as AMPK’s target in this regard. X53 X54 While, as noted, PPARα activation in the liver can boost AMPK activity systemically via induced production of FGF21 and adiponectin, it also enhances AMPK activation in hepatocytes and endothelium by promoting cytoplasmic translocation and subsequent activation of LKB1, an upstream activating kinase for AMPK. X55 X56 These reinforcing interactions are depicted in figure 1.

Hence, since AMPK and PPARα complement each other’s activity in multiple ways, the clinical complementary of metformin and fibrates is predictable.

**PROPOSAL: ASTAXANTHIN PLUS BERBERINE FOR CONTROL OF METABOLIC SYNDROME**

We propose that a nutraceutical regimen of berberine plus astaxanthin has the potential of replicating the utility of metformin+fenofibrate for improving the hyperlipidaemia and impaired glycaemic control that characterise metabolic syndrome and type 2 diabetes. Moreover, adding RYR to this regimen would be expected to provide additional control of LDL cholesterol. A regimen of berberine/RYR/astaxanthin might constitute a safe and usually well-tolerated strategy for optimising lipid profiles in patients in whom triglycerides and LDL cholesterol are both elevated, and HDL cholesterol depressed. Krill oil rich in astaxanthin (1 mg or more per gram) could be employed as an astaxanthin source, as this provides an esterified form of this carotenoid that has superior bioavailability, as well as health-protective omega-3 fatty acids, oxidised metabolites of which likewise act as PPARα.

---

**Figure 1** Legend interactions of AMPK and PPARα in promoting fatty acid oxidation and HDL production. Arrows reflect induction and/or activation. AMPK, AMP-activated kinase; CPT-1a, carnitine palmitoyl transferases-1a; FGF21, fibroblast growth factor 21; PGC-1a, PPARγ coactivator-1a; UCP-2, uncoupling protein-2.
agons. 57–60 Meta-analysis confirms the utility of krill oil supplementation for improving serum lipid profile. 61 Its efficacy with respect to modulating serum lipids, glucose and C reactive protein appears to be superior to that of fish oil. 62 63 The possibility of incorporating astaxanthin into hypolipidaemic nutraceutical regimens incorporating RYR, berberine and other agents was presciently envisioned by Cicero et al over a decade ago. 64

Contributors All the authors contributed to the final manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests JJD is the author of The Salt Fix and Superfuel. MM: Owner and science director of NutriGuard Research, a nutraceutical company which, among other things, sells berberine and astaxanthin supplements. JO: Chief medical officer and founder of CardioTabs, a nutraceutical company, has a major ownership interest in the company.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

Data availability statement No additional data are available.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES


